10-QPeriod: Q1 FY2022

BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2022

Filed May 9, 2022For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (ONC) reported its first-quarter 2022 financial results, showcasing a significant surge in product revenue, which more than doubled compared to the prior year period, primarily driven by strong sales of BRUKINSA® and tislelizumab in key markets like the U.S. and China. This growth was further bolstered by the inclusion of new products like BLINCYTO®, KYPROLIS®, and POBEVCY® in its distribution portfolio. However, total revenue experienced a substantial decline year-over-year, largely due to the absence of a significant upfront collaboration payment from Novartis that was recognized in the prior year quarter. Despite the revenue shift, the company's product sales demonstrate robust underlying demand, supported by expanding reimbursement coverage. Operationally, BeiGene reported a net loss for the quarter, a reversal from the net income in the prior year, primarily due to a substantial increase in research and development (R&D) and selling, general, and administrative (SG&A) expenses. These increased expenses reflect the company's strategic investments in expanding its global development organization, clinical pipeline, commercial capabilities, and broader R&D activities. The company maintained a strong liquidity position with significant cash and short-term investments, providing a runway for its ongoing operations and development programs.

Financial Highlights

54 data points
Beta

Revenue

$306.63M

78.7% Gross Margin

Net Income

-$435.20M

-141.9% Net Margin

EPS (Diluted)

$-0.33

Total Assets

$8.02B

Cash & Equivalents

$4.35B

Free Cash Flow

-$281.69M

Financial Statements
Beta
Revenue$306.63M
Cost of Revenue$65.24M
Gross Profit$241.39M
R&D Expenses$389.92M
SG&A Expenses$294.57M
Operating Expenses$749.91M
Operating Income-$443.29M
Interest Expense$5.53M
Net Income-$435.20M
EPS (Basic)$-0.33
EPS (Diluted)$-0.33
Shares Outstanding (Basic)1.33B
Shares Outstanding (Diluted)1.33B

Key Highlights

  • 1Product revenue surged by 146.5% to $261.6 million, driven by strong sales of BRUKINSA® and tislelizumab, and the addition of new in-licensed products.
  • 2Total revenue decreased by 49.4% to $306.6 million, primarily due to the absence of a significant upfront collaboration payment from Novartis recognized in the prior year quarter.
  • 3Net loss for the quarter was $434.3 million, compared to a net income of $66.5 million in the prior year, reflecting increased R&D and SG&A expenses.
  • 4Research and Development (R&D) expenses increased by 21.6% to $389.9 million, driven by the expansion of global development organization and clinical programs.
  • 5Selling, General, and Administrative (SG&A) expenses increased by 61.8% to $294.6 million, reflecting investments in commercial expansion and growing business operations.
  • 6Cash, cash equivalents, and restricted cash stood at $4.4 billion, and short-term investments were $1.9 billion, indicating a strong liquidity position.
  • 7The company ended the quarter with an accumulated deficit of $5.4 billion.

Frequently Asked Questions

Product revenue significantly increased by 146.5% to $261.6 million, primarily due to strong sales growth for its internally developed products, BRUKINSA® and tislelizumab, in markets including the U.S. and China. The inclusion of newly distributed in-licensed products such as BLINCYTO®, KYPROLIS®, and POBEVCY® also contributed to this growth.

Total revenue decreased by 49.4% to $306.6 million because the prior year quarter included a substantial upfront payment from the Novartis collaboration for tislelizumab. This one-time revenue recognition in the prior year is absent in the current quarter, leading to the year-over-year decline in total revenue, despite strong product sales growth.

For the three months ended March 31, 2022, BeiGene reported a net loss of $434.3 million, a reversal from the net income of $66.5 million reported in the same period last year. This loss is attributed to significant increases in R&D and SG&A expenses, reflecting the company's ongoing investments in its drug development pipeline and global commercial expansion.

The company has increased its R&D expenses by 21.6% to $389.9 million, supporting its expanding development organization and clinical programs. SG&A expenses rose by 61.8% to $294.6 million, driven by investments in commercial capabilities in key regions. These increases are strategic investments to support future growth and market penetration.

BeiGene maintains a strong liquidity position, with cash, cash equivalents, and restricted cash totaling $4.4 billion and short-term investments of $1.9 billion as of March 31, 2022. This robust financial standing is expected to fund its operations and capital expenditure requirements for at least the next 12 months.